Digestive Diseases and Sciences

, Volume 58, Issue 9, pp 2691–2704 | Cite as

Ultrasound Elastography for Fibrosis Surveillance Is Cost Effective in Patients with Chronic Hepatitis C Virus in the UK

  • C. Canavan
  • J. Eisenburg
  • L. Meng
  • K. Corey
  • C. Hur
Original Article



Chronic hepatitis C (HCV) is a significant risk factor for cirrhosis and subsequently hepatocellular carcinoma (HCC). HCV patients with cirrhosis are screened for HCC every 6 months. Surveillance for progression to cirrhosis and consequently access to HCC screening is not standardized. Liver biopsy, the usual test to determine cirrhosis, carries a significant risk of morbidity and associated mortality. Transient ultrasound elastography (fibroscan) is a non-invasive test for cirrhosis.


This study assesses the cost effectiveness of annual surveillance for cirrhosis in patients with chronic HCV and the effect of replacing biopsy with fibroscan to diagnose cirrhosis.


A Markov decision analytic model simulated a hypothetical cohort of 10,000 patients with chronic HCV initially without fibrosis over their lifetime. The cirrhosis surveillance strategies assessed were: no surveillance; current practice; fibroscan in current practice with biopsy to confirm cirrhosis; fibroscan completely replacing biopsy in current practice (definitive); annual biopsy; annual fibroscan with biopsy to confirm cirrhosis; annual definitive fibroscan.


Our results demonstrate that annual definitive fibroscan is the optimal strategy to diagnose cirrhosis. In our study, it diagnosed 20 % more cirrhosis cases than the current strategy, with 549 extra patients per 10,000 accessing screening over a lifetime and, consequently, 76 additional HCC cases diagnosed. The lifetime cost is £98.78 extra per patient compared to the current strategy for 1.72 additional unadjusted life years. Annual fibroscan surveillance of 132 patients results in the diagnosis one additional HCC case over a lifetime. The incremental cost-effectiveness ratio for an annual definitive fibroscan is £6,557.06/quality-adjusted life years gained.


Annual definitive fibroscan may be a cost-effective surveillance strategy to identify cirrhosis in patients with chronic HCV, thereby allowing access of these patients to HCC screening.


Hepatitis C Liver fibrosis Hepatocellular carcinoma Screening Health economics Outcomes research Radiology/imaging 


  1. 1.
    London: Health Protection Agency. Hepatitis C in the UK 2012. London: Health Protection Agency, Colindale.Google Scholar
  2. 2.
    Argeudas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679–690.CrossRefGoogle Scholar
  3. 3.
    Lemon SM, McGiven DR. Is hepatitis C virus carcinogenic? Gastroenterology. 2012;142:1274–1278.PubMedCrossRefGoogle Scholar
  4. 4.
    Bedossa P, Poynard T and the French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology. 1996;24:289–293.Google Scholar
  5. 5.
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. J Am Med Assoc. 2003;290:228–237.CrossRefGoogle Scholar
  6. 6.
    Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418–431.PubMedCrossRefGoogle Scholar
  7. 7.
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127:855–865.PubMedCrossRefGoogle Scholar
  8. 8.
    Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 2001;34:809–816.PubMedCrossRefGoogle Scholar
  9. 9.
    Grishchenko M, Grieve RD, Sweeting MJ, et al and the Trent HCV Study group. Cost-effectiveness of pegylated interferon and ribivarin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care. 2009;25:171–180.Google Scholar
  10. 10.
    Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health. 2011;14:1068–1077.PubMedCrossRefGoogle Scholar
  11. 11.
    Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–472.PubMedCrossRefGoogle Scholar
  12. 12.
    Benvegnu L, Alberti A. Patterns of hepatocellular carcinoma in HCV infection. Dig Dis Sci. 1996;14:49S–55S.CrossRefGoogle Scholar
  13. 13.
    Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730–739.PubMedCrossRefGoogle Scholar
  14. 14.
    Yano M, Kumada H, Kage M, et al. A long term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334–1340.PubMedCrossRefGoogle Scholar
  15. 15.
    Lok AS, Seeff LB, Morgan TR, et al and the HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–148.Google Scholar
  16. 16.
    Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26:34S–38S.PubMedCrossRefGoogle Scholar
  17. 17.
    Chang Y, Lairson DR, Chan W, Lu S-N, Aoki N. Cost effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk. J Eval Clin Pract. 2011;17:261–267.PubMedCrossRefGoogle Scholar
  18. 18.
    Ryder SC. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003;52:iii1–iii8.Google Scholar
  19. 19.
    Llovet M, Ducreux M. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.CrossRefGoogle Scholar
  20. 20.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.PubMedCrossRefGoogle Scholar
  21. 21.
    Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ. 1997;315:453–458.PubMedCrossRefGoogle Scholar
  22. 22.
    Sweeting MJ, De Angelis D, Neal KR, Ramsay ME, Irving WL, Wright M. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol. 2006;59:144–152.PubMedCrossRefGoogle Scholar
  23. 23.
    Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614–2618.PubMedCrossRefGoogle Scholar
  24. 24.
    West J, Card T. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology. 2010;139:1230–1237.PubMedCrossRefGoogle Scholar
  25. 25.
    Echosens. Registered technology of EchoSens. EchoSens, Paris. Available at: www.echosens.com.
  26. 26.
    Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Clin Hepatol. 2008;28:835–847.CrossRefGoogle Scholar
  27. 27.
    Castera L, Sebastiani G, Le Bail B, de Ledinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010;52:191–198.PubMedCrossRefGoogle Scholar
  28. 28.
    Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208.PubMedCrossRefGoogle Scholar
  29. 29.
    Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960–974.PubMedCrossRefGoogle Scholar
  30. 30.
    Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroebterol. 2010;44:214–219.CrossRefGoogle Scholar
  31. 31.
    Tzochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas BR, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54:650–659.CrossRefGoogle Scholar
  32. 32.
    Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicentre study (the FIBROSTIC study). J Hepatol. 2010;53:1013–1021.PubMedCrossRefGoogle Scholar
  33. 33.
    Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–350.PubMedCrossRefGoogle Scholar
  34. 34.
    Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS ONE. 2011;6:e26783.PubMedCrossRefGoogle Scholar
  35. 35.
    Poordad F, McCone J, Bacon BR, et al for the SPRINT-2 investigators. Boceprevir for untreated chronic HCV Genotype 1 infection. N Engl J Med. 2011;364:1195–1206.Google Scholar
  36. 36.
    Bacon BR, Gordon SC, Lawitz E, et al for the HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV Genotype 1 infection. N Engl J Med. 2011;364:1207–1217.Google Scholar
  37. 37.
    Wells CD, Murrill WB, Arguedas MR. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analysis in chronic liver disease. Dig Dis Sci. 2004;49:453–458.CrossRefGoogle Scholar
  38. 38.
    Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–1172.PubMedCrossRefGoogle Scholar
  39. 39.
    Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007;11:1–206.Google Scholar
  40. 40.
    Stamuli E, Kruger J, Hutton J. Cost-effectiveness of ultrasound elastography in the assessment of liver fibrosis. Economic report for the NHS Centre for Evidence-based Purchasing. 2009;CEP08053.Google Scholar
  41. 41.
    Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess. 2011;15.Google Scholar
  42. 42.
    Department of Health. 2010-11 Reference costs publication. Available at: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_131140. Accessed July 2012.
  43. 43.
    Treasury HM. The Green Book. Appraisal and Evaluation in Central Government. Treasury Guidance. London: TSO; 2003 (amended 2011).Google Scholar
  44. 44.
    Stout NK, Knudsen AB, Kong CY, McMahon P, Gazelle S. Calibration methods used in cancer simulation models and suggested guidelines. Pharmacoeconomics. 2009;27:533–545.PubMedCrossRefGoogle Scholar
  45. 45.
    Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the IPSOR-SMDM modelling good practice task force 7. Med Decis Mak. 2012;32:733–743.CrossRefGoogle Scholar
  46. 46.
    Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess. 2007;11:11.Google Scholar
  47. 47.
    Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion associated hepatitis C. N Engl J Med. 1995;332:1463–1466.PubMedCrossRefGoogle Scholar
  48. 48.
    Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687–1695.PubMedCrossRefGoogle Scholar
  49. 49.
    Andersson KL, Solomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418–1424.PubMedCrossRefGoogle Scholar
  50. 50.
    Abu Dayyeh BK, Yang M, Fuchs BC, et al for the HALT-C Trial Group. A functional polymorphism in the Epydermal growth factor gene is associated with risk of hepatocellular carcinoma. Gastroenterology. 2011;141:141–149.Google Scholar
  51. 51.
    Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetics with chronic liver disease. Liver Int. 2010;30:750–758.PubMedCrossRefGoogle Scholar
  52. 52.
    Pacanowski M, Amur S, Zinek I. New genetic discoveries and treatment for Hepatitis C. JAMA. 2012;307:1921–1922.PubMedCrossRefGoogle Scholar
  53. 53.
    Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cancer Physiol. 2006;207:261–270.Google Scholar
  54. 54.
    Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma: an emerging field for advanced technologies. J Hepatol. 2012;56:267–275.PubMedCrossRefGoogle Scholar
  55. 55.
    Adam R, Cailliez V, Majno P, et al. Normalised intrinsic mortality risk in liver transplantation: European liver transplant registry study. Lancet. 2000;356:621–627.Google Scholar
  56. 56.
    Canadian Agency for Drugs and Technologies in Health. Transient elastography (FibroScan) for non-invasive assessment of liver fibrosis. 2012Google Scholar
  57. 57.
    Fleming KM, Aithal GP, Card TR, West J. All-cause mortality in people with cirrhosis compared with the general population: a population-based cohort study. Liver Int. 2012;32:79–84.Google Scholar
  58. 58.
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–318.Google Scholar
  59. 59.
    Greten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer. 2005;92:1862–1868.Google Scholar
  60. 60.
    Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 1995;197:101–108.Google Scholar
  61. 61.
    Mondazzi L, Bottelli R, Brambilla G, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994;19:1115–1123.Google Scholar
  62. 62.
    Naugler WE, Sonnenberg A. Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl. 2010;16:1186–1194.Google Scholar
  63. 63.
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol. 2002:156:761–773.Google Scholar
  64. 64.
    Trevisani F, Santi V, Gramenzi A, et al for Italian Liver Cancer Group. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterology. 2007;102:2448–2457.Google Scholar
  65. 65.
    Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D. Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technol Assess. 2010;14:17–21.Google Scholar
  66. 66.
    The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20–29.Google Scholar
  67. 67.
    Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006;243:321–328.Google Scholar
  68. 68.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–700.Google Scholar
  69. 69.
    Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut. 2002;50:123–128.Google Scholar
  70. 70.
    Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 1999;19:311–322.Google Scholar
  71. 71.
    Ladabaum U, Cheng SL, Yao FY, Roberts JP. Cost effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2011;25:283–291.Google Scholar
  72. 72.
    Carr B, Carroll S, Muszbek N, Gondek K. Economic evaluation of Sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2010;25:1739–1746.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • C. Canavan
    • 1
  • J. Eisenburg
    • 2
  • L. Meng
    • 2
  • K. Corey
    • 3
  • C. Hur
    • 2
    • 3
  1. 1.Division of Epidemiology and Public HealthNottingham UniversityNottinghamUK
  2. 2.Institute for Technology AssessmentMassachusetts General HospitalBostonUSA
  3. 3.Gastrointestinal UnitMassachusetts General HospitalBostonUSA

Personalised recommendations